The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Blood Proteins For Early Discrimination Of DEmentias
Funder
National Health and Medical Research Council
Funding Amount
$498,412.00
Summary
bPRIDE aims to develop blood biomarkers for early and specific diagnosis of the main dementia types: Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies, and use these to develop diagnostic tests.
Investigating Biometal Dyshomeostasis In Dementia With Lewy Bodies
Funder
National Health and Medical Research Council
Funding Amount
$554,644.00
Summary
Dementia with Lewy bodies (DLB) is the second most common form of dementia after Alzheimer's disease (AD). Very little is known about what causes DLB and there are currently no effective therapeutics. An imbalance in naturally occurring biological metals such as iron and copper have been implicated in AD and Parkinson’s disease so this project will investigate if metals are involved in DLB. The ultimate goal of this project is to identify if metals are a valid target for future drug development.
Lewy Bodies In Patients With Dementia – Determining Common And Unique Mechanisms In Relation To Alzheimer’s Disease
Funder
National Health and Medical Research Council
Funding Amount
$604,644.00
Summary
Alzheimer’s disease is the most common type of dementia but often has multiple mixed pathologies. For example, Alzheimer post mortem brains may have abnormal accumulation of Lewy bodies in certain parts of the brains, and could be diagnosed as Lewy body disease. This may represent a skewed representation of some dementia subtypes. This project will identify the biological determinants of dementia patients with Lewy body disease for better understanding and future therapeutic targeting.
Non-Alzheimer’s Disease Degenerative Dementias: Identifying Prodromal Genetic/familial Phenotypes, Modifying Factors, And Protein Variations Involved In Progression
Funder
National Health and Medical Research Council
Funding Amount
$6,449,246.00
Summary
This proposal will generate new knowledge necessary for advancing the diagnosis of the non-Alzheimer’s disease dementias. We will identify the preclinical forms of frontotemporal dementia and Lewy body dementia using similar methods to those successfully employed to advance diagnosis of Alzheimer’s disease. Importantly, our team has the capacity to translate these protocols into clinical practice and into further advances in biological knowledge that is necessary for future therapeutic targeting
Cellular Effects Of Glucocerebrosidase (GBA) Mutations In Lewy Body Diseases
Funder
National Health and Medical Research Council
Funding Amount
$524,820.00
Summary
Approximately 1 in 100 people are carriers of mutations in the glucocerebrosidase (GBA) gene and are at considerably greater risk of diseases characterised clinically by parkinsonism and by the presence of Lewy body-related pathology. This study will provide tissue-based evidence of the cellular lipid and protein changes relating to Lewy body formation in patients with GBA mutations, providing the information necessary to identify the pathways and mechanisms involved.
Feasibility Of Minimally Invasive Deep Brain Stimulation Via An Endovascular Stent-electrode.
Funder
National Health and Medical Research Council
Funding Amount
$122,032.00
Summary
Neurocognitive decline in Parkinson's disease refers to the non-motor symptoms of the disease; these symptoms have increasingly become recognised as both prevalent, and evolving early in the disease course. While motor symptoms are treated with drugs and electrodes, the changes to patients� cognition, the progressive dementia, the psychosis and other symptoms progress with poor treatment. This research is designed to identify and understand targets so better treatments can be created.
Identifying Neuroimaging Based Biomarkers For Predicting Clinical Progression Along The Lewy Body Disease Spectrum
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
Lewy body dementias (LBD) comprise similar but heterogenous group of poorly understood disabling neurodegenerative conditions. This project aims to apply advanced neuroimaging techniques and novel psychological testing to patients at risk of Lewy body disorders as well individuals with established disease to identify novel biomarkers that may explain symptoms of these disorders as well as help predict development of LBD at its early stages when it may be amenable to neuroprotective treatments.
Dementia Related Deficits In Striatal Cholinergic Function And Decision-making
Funder
National Health and Medical Research Council
Funding Amount
$414,370.00
Summary
This proposal will provide essential new information on the role of deficits in decision-making associated with Parkinson’s disease dementia. We will use an innovative animal model to assess the influence of neurodegeneration and neuroinflammation the consequent loss of function in the neuronal systems supporting the learning and memory processes that contribute to goal-directed action, particularly the way new learning interacts with existing memory to guide choice and decision-making.
Discovery Of Novel Neurodegeneration Genes Via Next-generation Sequencing Technologies And High-throughput Cellular Assays
Funder
National Health and Medical Research Council
Funding Amount
$715,144.00
Summary
My research program aims to discover genes that are mutated in dementia, by identifying gene variants present in patients and absent in healthy people, and examining how these variants affect the function of cells. Identifying new dementia genes will reveal the biological processes that lead to brain cell death. Knowledge of these processes is crucial for the development of new treatments for the many people affected worldwide with dementia.